The German government’s drug policy is facing renewed internal debate, with the Federal Drug Commissioner, Hendrik Streeck, staunchly opposing proposals for a regulated distribution system for hard drugs. In an interview with the weekly publication “Die Zeit”, Streeck, a member of the Christian Democratic Union (CDU), voiced concerns about the unpredictable consequences of such a policy, emphasizing that “society is not a laboratory.
His reservations reflect a growing divergence within political and academic circles regarding the nation’s approach to drug use. Recent months have seen a resurgence in calls for a more liberal drug policy, largely spearheaded by the “Schildower Kreis” a prominent network of legal experts, social scientists, psychologists and social workers who advocate for alternative strategies. These proponents argue that current prohibitionist measures have demonstrably failed to curb drug use and instead contribute to a black market fueling crime and endangering users.
Streeck’s opposition highlights the inherent risk, in his view, of introducing sweeping reforms without a comprehensive understanding of their potential ramifications. He warned of the potential for “loss of control, new forms of misery and developments which one cannot later reverse” especially given the existing social challenges within Germany. Critically, he asserted that as a physician, he could not ethically endorse an experiment with such uncertain outcomes.
Rejecting the arguments presented by the Schildower Kreis and other advocates, Streeck signaled a continued prioritization of preventative measures. He insisted that the focus should remain on “empowering people so that they do not start consuming in the first place”. This signals a reinforcement of the CDU’s traditional stance – prioritizing abstinence-based programs and societal support – rather than exploring harm reduction models like regulated distribution, a trajectory increasingly popular in other European nations and championed by those seeking a pragmatic shift in drug policy. The deepening debate underscores the complex political and ethical considerations surrounding drug policy reform in Germany and the significant challenges in forging a consensus that balances public health, safety and individual liberties.